1. Background
2. Objectives
3. Methods
3.1. Study Design and Subjects
3.2. Measurement
3.3. Statistical Analysis
4. Results
| Population and Vaccine | Year | On Time | Not-vaccinated or Delayed Vaccination | Total Eligible Population | P-Value |
|---|---|---|---|---|---|
| Urban | |||||
| Hepatitis B | 2019 | 9004 (94) | 601 (6) | 9605 (100) | < 0.001 |
| 2020 | 8498 (89) | 1050 (11) | 9548 (100) | ||
| Bivalent oral polio (zero dose) | 2019 | 8754 (91) | 851 (9) | 9605 (100) | < 0.001 |
| 2020 | 8347 (87) | 1201 (13) | 9548 (100) | ||
| BCG | 2019 | 9000 (94) | 605 (6) | 9605 (100) | < 0.001 |
| 2020 | 8511 (89) | 1037 (11) | 9548 (100) | ||
| Rural | |||||
| Hepatitis B | 2019 | 1328 (84) | 258 (16) | 1586 (100) | < 0.001 |
| 2020 | 1352 (77.5) | 393 (22.5) | 1745 (100) | ||
| Bivalent oral polio (zero dose) | 2019 | 1275 (80) | 311 (20) | 1586 (100) | 0.009 |
| 2020 | 1338 (77) | 407 (23) | 1745 (100) | ||
| BCG | 2019 | 1316 (83) | 270 (17) | 1586 (100) | 0.001 |
| 2020 | 1365 (78) | 380 (22) | 1745 (100) |
Abbreviation: BCG, Bacillus Calmette-Guerin.
a Values are expressed as No. (%).
| Populations and Vaccines | Year | On Time | Not-vaccinated or Delayed Vaccination | Total Eligible Population | P-Value |
|---|---|---|---|---|---|
| Urban | |||||
| Bivalent oral polio (first dose) | 2019 | 8859 (97.8) | 197 (2.2) | 9056 (100) | < 0.001 |
| 2020 | 8847 (98.6) | 128 (1.4) | 8975 (100) | ||
| Pentavalent vaccine (first dose) | 2019 | 8852 (98.6) | 123 (1.4) | 9056 (100) | < 0.001 |
| 2020 | 8852 (97.7) | 204 (2.3) | 8975 (100) | ||
| Rural | |||||
| Bivalent oral polio (first dose) | 2019 | 1354 (90) | 146 (10) | 1500 (100) | < 0.004 |
| 2020 | 1459 (87) | 218 (13) | 1677 (100) | ||
| Pentavalent vaccine (first dose) | 2019 | 1355 (90) | 145 (10) | 1500 (100) | 0.002 |
| 2020 | 1456 (87) | 221 (13) | 1677 (100) |
a Values are expressed as No. (%).
| Populations and Vaccines | Year | On Time | Not-vaccinated or Delayed Vaccination | Total Eligible Population | P-Value |
|---|---|---|---|---|---|
| Urban | |||||
| Bivalent oral polio (second dose) | 2019 | 8422 (95) | 441 (5) | 8863 (100) | 0.283 |
| 2020 | 8398 (94.7) | 473 (5.3) | 8871 (100) | ||
| IPV | 2019 | 8319 (93.9) | 544 (6.1) | 8863 (100) | 0.056 |
| 2020 | 8386 (96.2) | 485 (3.8) | 8871 (100) | ||
| Pentavalent vaccine (second dose) | 2019 | 8403 (94.8) | 460 (5.2) | 8863 (100) | 0.418 |
| 2020 | 8393 (94.5) | 485 (5.5) | 8871 (100) | ||
| Rural | |||||
| Bivalent oral polio (second dose) | 2019 | 1255 (85) | 230 (15) | 1485 (100) | 0.064 |
| 2020 | 1366 (82) | 299 (18) | 1665 (100) | ||
| IPV | 2019 | 1223 (82) | 262 (18) | 1485 (100) | 0.378 |
| 2020 | 1351 (81) | 314 (19) | 1665 (100) | ||
| Pentavalent vaccine (second dose) | 2019 | 1253 (84) | 232 (16) | 1485 (100) | 0.026 |
| 2020 | 1355 (81) | 310 (19) | 1665 (100) |
a Values are expressed as No. (%).
| Populations and Vaccines | Year | On Time | Not-vaccinated or Delayed Vaccination | Total Eligible Population | P-Value |
|---|---|---|---|---|---|
| Urban | |||||
| Bivalent oral polio (third dode) | 2019 | 8155 (93) | 613 (3.9) | 8768 (100) | < 0.001 |
| 2020 | 7608 (87.7) | 1071 (12.3) | 8679 (100) | ||
| Pentavalent vaccine (third dose) | 2019 | 8033 (91.6) | 735 (8.4) | 8768 (100) | < 0.001 |
| 2020 | 7569 (87.2) | 1110 (12.8) | 8679 (100) | ||
| Rural | |||||
| Bivalent oral polio (third dode) | 2019 | 1190 (81) | 276 (19) | 1466 (100) | 0.052 |
| 2020 | 1271 (78) | 351 (22) | 1622 (100) | ||
| Pentavalent vaccine (third dose) | 2019 | 1166 (80) | 300 (20) | 1466 (100) | 0.089 |
| 2020 | 1249 (77) | 373 (23) | 1622 (100) |
a Values are expressed as No. (%).
| Population | Vaccine | Year | On Time | Not-vaccinated or Delayed Vaccination | Total Eligible Population | P-Value |
|---|---|---|---|---|---|---|
| Urban | MMR (first dose) | 2019 | 8018 (79.9) | 2011 (20.1) | 10029 (100) | < 0.001 |
| 2020 | 8738 (91) | 867 (9) | 9605 (100) | |||
| Rural | 2019 | 855 (56) | 677 (44) | 1532 (100) | ||
| 2020 | 1039 (71) | 427 (29) | 1466 (100) |
a Values are expressed as No. (%).
| Populations and Vaccines | Year | On Time | Not-vaccinated or Delayed Vaccination | Total Eligible Population | P-Value |
|---|---|---|---|---|---|
| Urban | |||||
| Bivalent oral polio (first booster) | 2019 | 6496 (69.9) | 2801 (30.1) | 9297 (100) | < 0.001 |
| 2020 | 7087 (80.8) | 1681 (19.2) | 8768 (100) | ||
| MMR (second dose) | 2019 | 6415 (69) | 2882 (31) | 9297 (100) | < 0.001 |
| 2020 | 6961 (79.4) | 1807 (20.6) | 8768 (100) | ||
| Trivalent vaccine (first booster) | 2019 | 6504 (70) | 2793 (30) | 9297 (100) | < 0.001 |
| 2020 | 7110 (81.1) | 1658 (18.9) | 8768 (100) | ||
| Rural | |||||
| Bivalent oral polio (first booster) | 2019 | 855 (56) | 677 (44) | 1532 (100) | < 0.001 |
| 2020 | 1039 (71) | 427 (29) | 1466 (100) | ||
| MMR (second dose) | 2019 | 852 (56) | 680 (44) | 1532 (100) | < 0.001 |
| 2020 | 1021 (70) | 445 (30) | 1466 (100) | ||
| Trivalent vaccine (first booster) | 2019 | 851 (56) | 681 (44) | 1532 (100) | < 0.001 |
| 2020 | 1041 (71) | 425 (29) | 1466 (100) |
a Values are expressed as No. (%).
| Populations and Vaccines | Year | On Time | Not-vaccinated or Delayed Vaccination | Total Eligible Population | P-Value |
|---|---|---|---|---|---|
| Urban | |||||
| Bivalent oral polio (second booster) | 2019 | 9078 (96.4) | 340 (3.6) | 9418 (100) | < 0.001 |
| 2020 | 8354 (87.8) | 1161 (12.2) | 9506 (100) | ||
| Trivalent vaccine (second booster) | 2019 | 8539 (90.7) | 879 (9.3) | 9418 (100) | < 0.001 |
| 2020 | 7932 (83.4) | 1574 (16.6) | 9605 (100) | ||
| Rural | |||||
| Bivalent oral polio (second booster) | 2019 | 851 (50.3) | 841 (49.7) | 1692 (100) | 0.863 |
| 2020 | 859 (50) | 859 (50) | 1718 (100) | ||
| Trivalent vaccine (second booster) | 2019 | 788 (46.6) | 904 (53.4) | 1692 (100) | 0.410 |
| 2020 | 825 (48) | 893 (52) | 1718 (100) |
a Values are expressed as No. (%).